Effect of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-23

Study Completion Date

2018-04-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overall goal of this study is to detect preclinical signs of HAPE by lung ultrasonography and evaluate the effectiveness of acetazolamide at decreasing pulmonary edema by using ultrasound.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Lung Ultrasound in High Altitude Lung Edema

NCT03117686

Pulmonary Edema

COMPLETED

Effect of High Altitude Exposure, Acclimatization and Re-exposure on Lung Water Content by Ultrasound

NCT02760186

Effect of High Altitude

COMPLETED NA

Susceptibility to High Altitude Pulmonary Edema in Subjects With Increased Hypoxic Pulmonary Vasoconstriction

NCT00559442

High Altitude Pulmonary Edema

COMPLETED NA

The Incidence of Subclinical High-altitude Pulmonary Oedema at High Altitude

NCT01794130

Acute Mountain Sickness Subclinical High Altitude Pulmonary Edema

COMPLETED

Pulmonary Function at High-Altitude

NCT00604227

Pulmonary Edema

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

High Altitude Pulmonary Edema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Acetazolamide normal dose

One (1) dose of 250mg of Acetazolamide

Group Type EXPERIMENTAL

Acetazolamide

Intervention Type DRUG

Administration of Acetazolamide

Placebo

One (1) dose of placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administration of Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acetazolamide

Administration of Acetazolamide

Intervention Type DRUG

Placebo

Administration of Placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

diamox

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. At least 18 years of age
2. Able to consent
3. English speaking
4. Trekking directly to Everest Base Camp

Exclusion Criteria

1. Age less than 18 years
2. Non-English speaking
3. Pregnant
4. Already had a diagnosis of acute mountain sickness, high-altitude cerebral edema, or high-altitude pulmonary edema
5. Been on a high-altitude trek 2 weeks prior to this study
6. Has taken acetazolamide 1 week prior to start of trek
7. Has a sulfa allergy
8. Has any type of acute or chronic pulmonary conditions

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes